LYMPHOCYTE COUNT IN PERIPHERAL BLOOD IS A SENSITIVE TOOL IN PRETREATMENT ASSESSMENT OF PATIENTS WITH UROLOGICAL

Abstract

We retrospectively studied correlation between lymphocyte count in peripheral blood of the patients with urological cancer (n = 789) and number of clinical parameters: cancer localization, stage of the disease, treatment outcome, complications. Mann- Whitney two-tailed test and logistic regression models were used. Lymphocyte counts (both absolute and relative) correlate with the cancer stage, and status of the disease, allowing differentiate patients with urological cancer, from healthy individuals, and from the cancer patients after radical surgery. In patients with kidney and bladder cancer, lymphocyte count allowed differentiate the stages of the disease. Lower rate of the reactivity of the patient to the cancer treatment is accurately predicted by the ALC and RLC: those in highest quartile for lymphocytes count have shorter postoperative recovery. Patients in lowest quartile demonstrated worst postoperative performance, including cases of early postoperative mortality due to weak somatic status. The study presents evidence that pretreatment lymphocyte count in the peripheral blood of patients with urological cancer is asensitive marker of cancer stage, and the reactivity of the patient to the cancer treatment, which can be used in the pretreatment assessment of the patient.